\documentclass[10pt]{article}

\usepackage{fullpage}
\usepackage{setspace}
\usepackage{parskip}
\usepackage{titlesec}
\usepackage[section]{placeins}
\usepackage{xcolor}
\usepackage{breakcites}
\usepackage{lineno}
\usepackage{hyphenat}





\PassOptionsToPackage{hyphens}{url}
\usepackage[colorlinks = true,
            linkcolor = blue,
            urlcolor  = blue,
            citecolor = blue,
            anchorcolor = blue]{hyperref}
\usepackage{etoolbox}
\makeatletter
\patchcmd\@combinedblfloats{\box\@outputbox}{\unvbox\@outputbox}{}{%
  \errmessage{\noexpand\@combinedblfloats could not be patched}%
}%
\makeatother


\usepackage{natbib}




\renewenvironment{abstract}
  {{\bfseries\noindent{\abstractname}\par\nobreak}\footnotesize}
  {\bigskip}

\titlespacing{\section}{0pt}{*3}{*1}
\titlespacing{\subsection}{0pt}{*2}{*0.5}
\titlespacing{\subsubsection}{0pt}{*1.5}{0pt}


\usepackage{authblk}


\usepackage{graphicx}
\usepackage[space]{grffile}
\usepackage{latexsym}
\usepackage{textcomp}
\usepackage{longtable}
\usepackage{tabulary}
\usepackage{booktabs,array,multirow}
\usepackage{amsfonts,amsmath,amssymb}
\providecommand\citet{\cite}
\providecommand\citep{\cite}
\providecommand\citealt{\cite}
% You can conditionalize code for latexml or normal latex using this.
\newif\iflatexml\latexmlfalse
\providecommand{\tightlist}{\setlength{\itemsep}{0pt}\setlength{\parskip}{0pt}}%

\AtBeginDocument{\DeclareGraphicsExtensions{.pdf,.PDF,.eps,.EPS,.png,.PNG,.tif,.TIF,.jpg,.JPG,.jpeg,.JPEG}}

\usepackage[utf8]{inputenc}
\usepackage[ngerman,english]{babel}



\usepackage{float}








\begin{document}

\title{Improved method of synthesizing {[}\textsuperscript{11}C{]}MK7246 for
imaging beta cell mass~}



\author[1]{SRSTT Radiopharmaconnect}%
\affil[1]{Radiopharmaconnect}%


\vspace{-1em}



  
  \date{March 15, 2025}


\begingroup
\let\center\flushleft
\let\endcenter\endflushleft
\maketitle
\endgroup








\sloppy


\textbf{}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/CAFACHEM/CAFACHEM}

\end{center}
\end{figure}

\textbf{\href{https://www.srsweb.org/cafachem2020}{\textbf{\textbf{CAFACHEM~2020}}}}
organizers are grateful for the support
of~\textbf{\href{https://www.pmod.com/web/}{\textbf{\textbf{\textbf{PMOD}}}}}

\par\null\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/pmod/pmod}

\end{center}
\end{figure}

\textbf{Authors:~ Bo Zhang}\textsuperscript{1}, Pierre
Cheung\textsuperscript{1}, Emmi Puuvuori\textsuperscript{1}, Amin
Mohammad\textsuperscript{1}, Sofie Ye\textsuperscript{1}, Olle
Korsgren\textsuperscript{2}, Luke Odell\textsuperscript{1}, Olof
Eriksson\textsuperscript{1}, Jonas Eriksson\textsuperscript{1} \textbf{}

\textbf{} \textsuperscript{1} Science for Life Laboratory, Department of
Medicinal Chemistry, Uppsala University, Uppsala, Sweden;
\textsuperscript{2} Department of Immunology, Genetics and Pathology,
Clinical Immunology, Uppsala University, Uppsala, Sweden \textbf{}

\par\null

\textbf{\textbf{Background}}

\textbf{\textbf{}} Loss of beta cell mass (BCM) is a hallmark of
diabetes that could be potentially studied non-invasively by Positron
Emission Tomography (PET). MK7246 is an antagonist of the GPR44 receptor
(also called PGD2 or CRTH2) that is selectively expressed on pancreatic
beta cells. \textbf{\textbf{}}

\par\null

\textbf{\textbf{Aims}}

\textbf{\textbf{}} We have previously synthesized
{[}\textsuperscript{11}C{]}MK7246 and used this radiotracer for
preclinical PET evaluation of BCM.\textsuperscript{1} However, the
synthesis method afforded low radiochemical yield (RCY) and we aimed to
develop an improved method. \textbf{\textbf{}}

\par\null

\textbf{Methods}

\textbf{} The precursor (figure 1) was reacted with
{[}\textsuperscript{11}C{]}methyl iodide in DMF in the presence of DBU
at 110\selectlanguage{ngerman}ºC for 4 min followed by deprotection with NaOH at 75ºC for 4min.
After prep-HPLC purification and solid phase extraction, the product was
injected in 8 pigs with and without 1mg/kg non-radioactive MK7246.

\textbf{~}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Screenshot-2020-08-01-at-16-01-55/Screenshot-2020-08-01-at-16-01-55}
\caption{{Synthesis of~{[}\textsuperscript{11}C{]}MK7246
{\label{148726}}%
}}
\end{center}
\end{figure}

\textbf{}

\textbf{Results and Conclusion}

The product activity was improved from 270\selectlanguage{ngerman}±120MBq to 800±152MBq and the
RCY was tripled from 5±2\% to 14\%±1\%. The radiochemical purity (RCP)
initially reduced to 84±3\% due to radiolysis but was improved to 95±4\%
by adding ascorbic acid. PET imaging showed specific binding in the
pancreas of all pigs. \textbf{}

\par\null

\textbf{References}

\textbf{1.} Eriksson J \emph{et al}. Synthesis and preclinical
evaluation of the CRTH2 antagonist {[}\textsuperscript{11}C{]}MK-7246 as
a novel PET tracer and potential surrogate marker for pancreatic
beta-cell mass. \emph{Nucl Med Biol}. 2019;71:1--10.

\textbf{}\selectlanguage{english}
\begin{figure}[H]
\begin{center}
\includegraphics[width=0.70\columnwidth]{figures/Screenshot-2020-07-10-at-12-20-47/Screenshot-2020-07-10-at-12-20-47}

\end{center}
\end{figure}

\selectlanguage{english}
\FloatBarrier
\end{document}

